Immunitas Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
830 Winter St Ste 2, Waltham, Massachuse...Phone Number
(617) 648-9100Website
www.immunitastx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
1
1
1
About Immunitas Therapeutics
Immunitas is an a single cell genomics-based therapeutics company that enables rapid target identification and validation in parallel with antibody discovery and engineering. The comany is based in Waltham, Massachusetts.Explore more
Immunitas Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunitas Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Immunitas Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Immunitas Therapeutics
Click to see if Immunitas Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Immunitas Therapeutics launches new products
Check out if Immunitas Therapeutics is spiking on competitors!
Check if Immunitas Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Immunitas Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Immunitas Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Immunitas Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immunitas Therapeutics
Compare insights from companies similar to Immunitas Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunitas Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Immunitas Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Immunitas Therapeutics.
Immunitas Therapeutics financials insights
Gather financial insights about Immunitas Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$39M
2021
Series B
$58M
Immunitas Therapeutics Tech Stack
A closer look at the technologies used by Immunitas Therapeutics
Most Recent Scoops
Promotion
Executive Move
Promotion
Executive Move
New Hire
Executive Move
Promotion
Executive Move
Left Company
Executive Move
Immunitas Therapeutics News & Media
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
IMT-009 was generally well tolerated as monotherapy and in combination with fruquintinib, demonstrating early signs of anti-tumor activity in heavily pretreated patients Translational findings suggest biomarkers associated with tertiary lymphoid structures may help identify patients most...Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting
WALTHAM, Mass., March 17, 2026 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for patients with autoimmune diseases and cancer, today announced it will...Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
Preclinical data expand potential of IMT-009, confirming presence of CD161 expressing T cells in anti-PD1 non-responder tumors and demonstrating enhanced T cell mediated cytotoxicity with combination treatment of IMT-009 and anti-PD1 Results support clinical evaluation of IMT-009-anti-PD1...Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting
Preclinical data demonstrate presence of CD161 expressing T cells in anti-PD1 non-responder tumors and enhanced T cell mediated cytotoxicity with combination treatment of IMT-009 and anti-PD1, providing rationale for clinical studies assessing combination treatment approaches WALTHAM,...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Immunitas Therapeutics
Sign Up For FreeTo access detailed company insights
Immunitas is an a single cell genomics-based therapeutics company that enables rapid target identification and validation in parallel with antibody discovery and engineering. The comany is based in Waltham, Massachusetts.... Read More
